Gyre Therapeutics reports Q3 revenue of $30.6 million and net income of $5.9 million

Reuters11-07

<a href="https://laohu8.com/S/GYRE">Gyre Therapeutics</a> reports Q3 revenue of $30.6 million and net income of $5.9 million

Gyre Therapeutics Inc. reported revenue of $30.6 million for the third quarter of 2025, a 20% increase year-over-year, driven by growth in ETUARY sales and contributions from Etorel and Contiva. Net income for the quarter doubled to $5.9 million, while adjusted net income rose to $8.8 million. Operating income increased by 64% to $6.9 million, and basic earnings per share improved to $0.04 from $0.01 a year earlier. For the nine months ended September 30, 2025, revenues totaled $79.4 million compared to $77.9 million for the same period in 2024. The company revised its full-year 2025 revenue guidance to $115-118 million, down from $118-128 million, due to a slower-than-expected rollout of Etorel and market uncertainty related to China's centralized procurement policy. Marketing efforts were refocused on ETUARY during the third quarter, with expectations for continued ETUARY sales growth in the fourth quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571120-en) on November 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581009971?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581009971","market":"us","top_or_hot":-1,"title":"Gyre Therapeutics reports Q3 revenue of $30.6 million and net income of $5.9 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GYRE\">Gyre Therapeutics</a> reports Q3 revenue of $30.6 million and net income of $5.9 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Gyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. reported revenue of $30.6 million for the third quarter of 2025, a 20% increase year-over-year, driven by growth in ETUARY sales and contributions from Etorel and Contiva. Net income for the quarter doubled to $5.9 million, while adjusted net income rose to $8.8 million. Operating income increased by 64% to $6.9 million, and basic earnings per share improved to $0.04 from $0.01 a year earlier. For the nine months ended September 30, 2025, revenues totaled $79.4 million compared to $77.9 million for the same period in 2024. The company revised its full-year 2025 revenue guidance to $115-118 million, down from $118-128 million, due to a slower-than-expected rollout of Etorel and market uncertainty related to China's centralized procurement policy. Marketing efforts were refocused on ETUARY during the third quarter, with expectations for continued ETUARY sales growth in the fourth quarter.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571120-en) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gyre Therapeutics reports Q3 revenue of $30.6 million and net income of $5.9 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGyre Therapeutics reports Q3 revenue of $30.6 million and net income of $5.9 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GYRE\">Gyre Therapeutics</a> reports Q3 revenue of $30.6 million and net income of $5.9 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Gyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. reported revenue of $30.6 million for the third quarter of 2025, a 20% increase year-over-year, driven by growth in ETUARY sales and contributions from Etorel and Contiva. Net income for the quarter doubled to $5.9 million, while adjusted net income rose to $8.8 million. Operating income increased by 64% to $6.9 million, and basic earnings per share improved to $0.04 from $0.01 a year earlier. For the nine months ended September 30, 2025, revenues totaled $79.4 million compared to $77.9 million for the same period in 2024. The company revised its full-year 2025 revenue guidance to $115-118 million, down from $118-128 million, due to a slower-than-expected rollout of Etorel and market uncertainty related to China's centralized procurement policy. Marketing efforts were refocused on ETUARY during the third quarter, with expectations for continued ETUARY sales growth in the fourth quarter.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571120-en) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL7qhZlX:1","article_id":"2581009971","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581009971","pubTimestamp":1762513222,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Gyre Therapeutics Inc. reported revenue of $30.6 million for the third quarter of 2025, a 20% increase year-over-year, driven by growth in ETUARY sales and contributions from Etorel and Contiva. Net income for the quarter doubled to $5.9 million, while adjusted net income rose to $8.8 million. Operating income increased by 64% to $6.9 million, and basic earnings per share improved to $0.04 from $0.01 a year earlier. For the nine months ended September 30, 2025, revenues totaled $79.4 million compared to $77.9 million for the same period in 2024. The company revised its full-year 2025 revenue guidance to $115-118 million, down from $118-128 million, due to a slower-than-expected rollout of Etorel and market uncertainty related to China's centralized procurement policy. Marketing efforts were refocused on ETUARY during the third quarter, with expectations for continued ETUARY sales growth in the fourth quarter.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","GYRE":"Gyre Therapeutics","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"Gyre Therapeutics报告第三季度营收为3060万美元，净利润为590万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GYRE":0.9,"NDAQ":0.9},"content_text":"Gyre Therapeutics reports Q3 revenue of $30.6 million and net income of $5.9 million\n    \n\n        Gyre Therapeutics Inc. reported revenue of $30.6 million for the third quarter of 2025, a 20% increase year-over-year, driven by growth in ETUARY sales and contributions from Etorel and Contiva. Net income for the quarter doubled to $5.9 million, while adjusted net income rose to $8.8 million. Operating income increased by 64% to $6.9 million, and basic earnings per share improved to $0.04 from $0.01 a year earlier. For the nine months ended September 30, 2025, revenues totaled $79.4 million compared to $77.9 million for the same period in 2024. The company revised its full-year 2025 revenue guidance to $115-118 million, down from $118-128 million, due to a slower-than-expected rollout of Etorel and market uncertainty related to China's centralized procurement policy. Marketing efforts were refocused on ETUARY during the third quarter, with expectations for continued ETUARY sales growth in the fourth quarter.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571120-en) on November 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581009971","isCrawlerRequest":true}